Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
Pavlo Gilchuk(AstraZeneca (Japan)), James E. Crowe(Vanderbilt University Medical Center), Robert H. Carnahan(Vanderbilt University Medical Center), Alexander Bukreyev(Galveston College), Prashant K. Singh(Vanderbilt University), Matthew S. Bramble(Children's National), Natalia A. Kuzmina(Galveston College), Kai Huang(Galveston College), Philipp A. Ilinykh(Houston Methodist), Patrick Mukadi(National Institute of Biomedical Research), George K. Lewis(University of Maryland, Baltimore), Nurgun Kose(Vanderbilt University Medical Center), Erica H. Parrish(Vanderbilt University Medical Center), Anne W. Rimoin(University of California, Los Angeles), Elad Binshtein, Hannah L. Turner(Scripps Research Institute), Alexander M. Sevy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robin Bombardi(Vanderbilt University Medical Center), Edgar Davidson(Integral Molecular (United States)), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Nicole A. Hoff, Aubrey L. Bryan(Integral Molecular (United States)), Chiara Orlandi(University of Maryland, Baltimore), Benjamin J. Doranz(Integral Molecular (United States)), Melanie D. Ohi(Vanderbilt University), Andrew B. Ward(Scripps Research Institute), Erica Ollmann Saphire(La Jolla Institute for Immunology), Robin Flinko(University of Maryland, Baltimore), Andrew I. Flyak(Vanderbilt University), Marnie L. Fusco(Scripps Research Institute), Jean Jacques Muyembe-Tamfum(National Institute of Biomedical Research), Bronwyn M. Gunn(Washington State University)
Cited by 90
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
An evidence review of face masks against COVID-19
|Proceedings of the National Academy of Sciences|2021|1.3k
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k